NMPA approves felzartamab (Jingfei) + lenalidomide and dexamethasone for treating multiple myeloma patients who have received at least one prior line of therapy
TJ Biopharma and Biogen (Nasdaq: BIIB) today announced that felzartamab for injection (trade name: Jingfei®, hereinafter referred to as “felzartamab”) has been approved for marketing by the National Medical Products Administration (NMPA) of China for use in combination with lenalidomide and dexamethasone in the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy.
Share:
More News
“Completing enrollment in the Phase III TIGeR-PaC trial marks a major milestone for RenovoRx,” said Ramtin Agah, M.D., Executive Chairman, Chief Medical Officer, and Founder of RenovoRx. “TIGeR-PaC is the cornerstone of our clinical development program, and we are now closer than ever in our efforts to validate IAG and
“Zipalertinib is a compound created through Taiho Pharmaceutical’s proprietary drug discovery technology,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “Achieving positive results in this Phase 3 trial in the first-line setting represents an important milestone for this program. We will continue to work closely with Taiho Oncology
“We are pleased to welcome C-CAR039 back to our hematology malignancy portfolio,” said Tony (Bizuo) Liu, Chairman and Chief Executive Officer of AbelZeta. “Clinical trial results to date have demonstrated the favorable safety and encouraging efficacy of C-CAR039 in r/r LBCL patients. We believe that it has potential to help
“We are delighted to transform our discoveries in glioblastoma into a promising new vaccine program with EVX-05, which could hold a significant therapeutic potential in area of massive unmet medical need. We have an outstanding collaboration with Duke University and now see the huge benefits of combining their extensive disease